XML 13 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Shares
Treasury Stock
Capital in Excess of Par Value
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022   188,560        
Beginning balance at Dec. 31, 2022 $ 366,638 $ 19   $ 3,574,719 $ (6,907) $ (3,201,193)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Shares issued under equity compensation plans (in shares)   675        
Stock-based compensation 10,019     10,019    
Comprehensive income (loss) (135,792)       1,226 (137,018)
Ending balance (in shares) at Mar. 31, 2023   189,235        
Ending balance at Mar. 31, 2023 $ 240,865 $ 19   3,584,738 (5,681) (3,338,211)
Beginning balance (in shares) at Dec. 31, 2023 191,384 191,384        
Beginning balance at Dec. 31, 2023 $ 130,987 $ 19   3,608,137 80 (3,477,249)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Shares issued under equity compensation plans (in shares)   525        
Shares issued under equity compensation plans 3     3    
Stock-based compensation 6,000     6,000    
Repurchase of common stock from Bristol-Myers Squibb (in shares)   (8,285) 8,285      
Repurchase of common stock from Bristol-Myers Squibb (3,000)   $ (3,000)      
Issuance of prefunded warrant 30,000     30,000    
Comprehensive income (loss) $ (37,285)       (483) (36,802)
Ending balance (in shares) at Mar. 31, 2024 183,624 183,624 8,285      
Ending balance at Mar. 31, 2024 $ 126,705 $ 19 $ (3,000) $ 3,644,140 $ (403) $ (3,514,051)